中国神经再生研究(英文版) ›› 2016, Vol. 11 ›› Issue (6): 944-950.doi: 10.4103/1673-5374.184493

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

罗格列酮可减轻弥漫性轴索损伤:其机制在于减少tau蛋白丢失并上调caveolin-1表达

  

  • 收稿日期:2015-12-22 出版日期:2016-06-30 发布日期:2016-06-30
  • 基金资助:

    新世纪优秀人才支持计划(NCET-05-0831)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression

Yong-lin Zhao, Jin-ning Song*, Xu-dong Ma, Bin-fei Zhang, Dan-dong Li, Hong-gang Pang   

  1. Department of Neurosurgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China
  • Received:2015-12-22 Online:2016-06-30 Published:2016-06-30
  • Contact: Jin-ning Song, M.D., jinningsong@126.com.
  • Supported by:

    This study was funded by the New Century Supporting Programs to Excellent Talents in China, No. NCET-05-0831.

摘要:

有研究表明,罗格列酮可上调caveolin-1蛋白表达,对急慢性脑损伤有保护作用。为此,实验假设对急慢性脑损伤有保护作用的药物-罗格列酮,可通过上调caveolin-1蛋白的表达,抑制β淀粉样前体蛋白的表达及tau蛋白的丢失和tau蛋白异常磷酸化,以此来保护弥漫性轴索损伤。实验将弥漫性轴索损伤模型大鼠腹腔注射罗格列酮后发现,大鼠大脑皮质β淀粉样前体蛋白和p-tau (S404)蛋白表达明显降低,而total tau和caveolin-1蛋白表达明显上调。结果表明,罗格列酮可通过抑制β淀粉样前体蛋白、p-tau (S404)蛋白的表达,减少total tau蛋白的丢失,对弥漫性轴索损伤起神经保护作用,其机制与上调caveolin-1的表达有关。 

orcid: 0000-0002-0620-8983 (Jin-ning Song)

关键词: 神经再生, 弥漫性轴索损伤, 罗格列酮, tau蛋白过度磷酸化, tau蛋白, 小窝蛋白-1, 大鼠, β淀粉样前体蛋白, 丝氨酸404位点, 大脑皮质, 免疫组织化学, 免疫印迹法

Abstract:

Rosiglitazone up-regulates caveolin-1 levels and has neuroprotective effects in both chronic and acute brain injury. Therefore, we postulated that rosiglitazone may ameliorate diffuse axonal injury via its ability to up-regulate caveolin-1, inhibit expression of amyloid-beta precursor protein, and reduce the loss and abnormal phosphorylation of tau. In the present study, intraperitoneal injection of rosiglitazone significantly reduced the levels of amyloid-beta precursor protein and hyperphosphorylated tau (phosphorylated at Ser404 (p-tau (S404)), and it increased the expression of total tau and caveolin-1 in the rat cortex. Our results show that rosiglitazone inhibits the expression of amyloid-beta precursor protein and lowers p-tau (S404) levels, and it reduces the loss of total tau, possibly by up-regulating caveolin-1. These actions of rosiglitazone may underlie its neuroprotective effects in the treatment of diffuse axonal injury.

Key words: nerve regeneration, diffuse axonal injury, rosiglitazone, hyperphosphorylated tau, total tau, caveolin-1, rats, amyloid precursor protein, ser404, cortex, immunocytochemistry, western blot assay, neural regeneration